







# Prevalence, characteristics, and impact of adverse events in 34 Madrid hospitals. The ESHMAD study

José L. Valencia-Martín<sup>1,2</sup>  | Jorge Vicente-Guijarro<sup>3,4</sup>  | Diego San Jose-Saras<sup>3,5</sup>  |  
Paloma Moreno-Nunez<sup>3,4</sup>  | Alberto Pardo-Hernández<sup>6,7</sup>  |  
Jesús María Aranz-Andrés<sup>3,4,8</sup>  | ESHMAD Director Group and external advisers

<sup>1</sup>Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Virgen del Rocío, Sevilla, Spain

<sup>2</sup>Departamento de Medicina Preventiva y Salud Pública, Universidad de Sevilla, Sevilla, Spain

<sup>3</sup>Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

<sup>4</sup>Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja, Logroño, Spain

<sup>5</sup>Universidad de Alcalá, Facultad de Medicina y Ciencias de la Salud, Departamento de Biología de Sistemas, Alcalá de Henares, Spain

<sup>6</sup>Subdirección General de Calidad Asistencial y Cooperación Sanitaria, Consejería de Sanidad de la Comunidad de Madrid, Madrid, Spain

<sup>7</sup>Departamento de Especialidades Médicas y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain

<sup>8</sup>Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain

## Correspondence

Diego San José Saras, MD, MPH,  
Servicio de Medicina Preventiva y  
Salud Pública, Hospital Universitario  
Ramón y Cajal, IRYCIS, Madrid, 28034  
Spain; Universidad de Alcalá, Facultad  
de Medicina y Ciencias de la Salud,  
Departamento de Biología de Sistemas,  
Alcala de Henares, 28871 Spain.  
Email: [diego.sanjose@salud.madrid.org](mailto:diego.sanjose@salud.madrid.org)

## Abstract

**Introduction:** Adverse Events (AE) are one of the main problems in healthcare. Therefore, many policies have been developed worldwide to mitigate their impact. The Patient Safety Incident Study in Hospitals in the Community of Madrid (ESHMAD) measures the results of them in the region.

**Methods:** Cross-sectional study, conducted in May 2019, in hospitalised patients in 34 public hospitals using the *Harvard Medical Practice Study* methodology. A logistic regression model was carried out to study the association of the variables with the presence of AE, calibrated and adjusted by patient.

**Results:** A total of 9975 patients were included, estimating a prevalence of AE of 11.9%. A higher risk of AE was observed in patients with surgical procedures (OR[CI95%]: 2.15[1.79 to 2.57], vs. absence), in Intensive Care Units (OR[CI95%]: 1.60[1.17 to 2.17], vs. Medical) and in hospitals of medium complexity (OR[CI95%]: 1.45[1.12 to 1.87], vs. low complexity). A 62.6% of AE increased the length of the stay or it was the cause of admission, and 46.9% of AE were considered preventable. In 11.5% of patients with AE, they had contributed to their death.

**Conclusions:** The prevalence of AE remains similar to the previously estimated one in studies developed with the same methodology. AE keep leading to longer

ESHMAD Director Group and external advisers Members of the research group present in Contributors section.

José L. Valencia-Martín and Jorge Vicente-Guijarro contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *European Journal of Clinical Investigation* published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

hospital stays, contributing to patient's death, showing that it is necessary to put focus on patient safety again. A detailed analysis of these events has enabled the detection of specific areas for improvement according to the type of care, centre and patient.

## 1 | INTRODUCTION

Adverse events (AE) related to healthcare include all the Patient Safety Incidents that produce harm to patients.<sup>1</sup> AE are a significant health problem, since they reduce the quality level of care and can lead to excess morbidity and mortality.<sup>2,3</sup> Likewise, the AE as a whole are the third cause of death in the United States (around 250,000 per year; 98,000 in hospital settings),<sup>4</sup> and have a significant economic impact (losses of over €194 million were estimated in Ireland in 2017).<sup>5</sup>

Since the publication of the report *To Err is Human*<sup>6</sup>, in 2000, the detection and epidemiological tracking of AE in the hospital setting has led to the implementation of actions to improve patient safety, on both at care and organisational level. Although AE have been studied in different care settings, AE are particularly prevalent in the hospital setting, making it an ideal environment to implement preventive barriers.<sup>6</sup>

Several methods have been developed for the identification and surveillance of AE, ranging from the Global Trigger Tool<sup>7</sup> to the instrument previously developed by the Harvard Medical Practice Study,<sup>8</sup> which provides more complete information on AE, their nature and impact, and is the most widely used in the hospital setting.<sup>5,9-19</sup>

In Spain, concern for patient safety has grown in parallel with that in other European countries, allowing the performance of the Spanish National Study on Hospitalisation-Related Adverse Events (ENEAS),<sup>13</sup> a pioneer quantifying the national incidence of AE in the hospital setting and which found an incidence of 9.3%. Studies were also conducted in the out-of-hospital setting, particularly the 'Patient Safety in Primary Care Study' in 2007 which found a point prevalence of 0.8%,<sup>20</sup> and the 'Adverse effects at assisted patient care centres and living facilities' in 2011, which showed that complications in care have the biggest impact at that level.<sup>21</sup>

All this led to the promotion of public policies in Spain. 'Patient Safety Strategy of the National Health System'<sup>22</sup> and 'Patient Safety Strategy of the Community of Madrid',<sup>23</sup> both for the period 2015–2020, are the most recently developed strategic plans, at the national and local level, respectively. The fundamental pillars of both were to promote a safety culture at all levels of care, the

development of safety incident notification systems and the promotion of safety practices.

Within the Community of Madrid, one of the strategic objectives was related to making a pioneering measurement of AE in all the hospitals in the region and the scientific dissemination of the results. In this context, the Patient Safety Incident Study of Hospitals in the Community of Madrid (ESHMAD) arises, whose main objective is to identify the prevalence, characteristics and impact of AE in hospitals in the region, as well as to analyse the factors associated with the development of AE.

## 2 | MATERIALS AND METHODS

### 2.1 | Design

An observational descriptive cross-sectional study was carried out in all public hospitals in the Community of Madrid (34 hospitals in total), comprising 6 low complexity hospitals (with <5 clinical specialities), 13 medium complexity hospitals (5 to 10 clinical specialities), 8 high complexity hospitals (highly specialised, >10 clinical specialities), 2 support hospitals (caring for patients in the sub-acute phase of reversible diseases), 3 long-term care hospitals (caring for patients requiring chronic care) and 2 psychiatric hospitals. To construct the sample, each centre carried out a single cross-sectional cut of hospitalised patients at the start of the care activity on a day in May 2019. Patients needed to have a hospital admission at the time of the cut and the only patients excluded were those in emergency units. A patient who was included in one hospital could not be included in another centre.

There was a scientific directorate, based at the Health Department of the Community of Madrid and the Hospital Universitario Ramón y Cajal, responsible for designing, planning, training, providing scientific technical support and analysing the results. A train-the-trainer structure was implemented, with one coordinator per centre for each phase of the study.<sup>24</sup> Each hospital was responsible for assigning the study to a team of reviewers, who received specific training for the study. The coordinator of each phase was in charge of carrying out a validation of the data, agreeing with the reviewer when there were discrepancies when categorising an event.

The study was conducted in two phases by clinical records review. It was based on the methodology of Brennan et al. and the Harvard Practice Medical Study<sup>8</sup> and the previous experience of the ENEAS<sup>13</sup> and IBEAS<sup>25</sup> study:

1. Screening for AE. After including all patients with a minimum stay of 24 hours following the methodology of the EPINE study,<sup>26</sup> the ESHMAD screening tool was used. It is an expanded questionnaire that includes two validated tools: the EPINE form,<sup>27</sup> which allows collecting all epidemiological variables, and the AE Screening Guide,<sup>8</sup> designed to identify warning signs of possible AE. Variables related to the healthcare provided and the diagnostic-therapeutic procedure performed were also collected. According to the Harvard Medical Practice Study methodology, this phase could be performed by any healthcare worker recruited.
2. Review, confirmation and characterisation of the possible AE that obtained a positive result in the previous phase of screening. An adaptation of the Modular Review Form 2 (MRF2),<sup>28</sup> translated after the experience with the ENEAS<sup>13</sup> and IBEAS<sup>25</sup> studies, was used to gather structured information on the characteristics, consequences, impact and avoidability of each potential AE. It was conducted on discharge or, if still in hospital, 30 days after screening. This phase was carried out by a specifically trained physician.

The data were collected using a paper version of both tools. After that, the data were uploaded to a specific informatic software designed for the study, with data protection and safeguard mechanisms.

More information about the study design can be found in the publication of Valencia-Martín et al. in 2021.<sup>24</sup> Reporting of the study conforms to broad EQUATOR guidelines.<sup>29</sup>

## 2.2 | Variables collected

As established by the Conceptual Framework of the International Classification for Patient Safety, published by the World Health Organisation in 2009, AE were classified as every incident during healthcare that causes physical harm, psychological damage or death to the patient; their degree of avoidability was also measured.<sup>1,30</sup>

Subsequently, an analysis of the relationship between AE and healthcare was conducted on a 6-point scale, requiring 4 or more to be considered linked. The same scale was used to assess their avoidability.

It was also collected intrinsic risk factors (IRF) of the patient at the moment of admission, (renal failure, cardiovascular disease, neoplasia, chronic obstructive

pulmonary disease [EPOC], immunodeficiency, neutropenia, liver cirrhosis, hypoalbuminaemia, pressure ulcers, impaired mobility, sensory deficits, obesity and active smoking) and extrinsic risk factors (ERF) related to the healthcare delivered to the patient at the moment of screening, (previous surgery, peripheral vascular catheter, central vascular catheter, urinary catheterisation, intubation and number of drugs prescribed at the time of review). Age was classified into '<65 years' and '≥65 years' and IRF and ERF according to the number of factors present, allowing comparability with previous studies.<sup>5,13,25</sup> More information about these factors can be consulted at the Supplementary Material (Table S1).

The type of AE (according to the MRF2 classification: 'Hospital acquired infection (HAI)', 'Complications in care', 'Complications of a procedure', 'Adverse effects of medication' and 'Other consequences'),<sup>28</sup> its causes and impacts in the form of consequential procedures, and severity (according to the World Health Organisation: 'mild', if it did not modify hospital stay; 'moderate', if it resulted in readmission or increased hospital days; and 'severe', if it led to a surgical intervention or contributed to the patient's death<sup>30</sup>) was also collected.

The disability of the AE was measured according to the clinical records with the Rosser Scale,<sup>31</sup> which allows to evaluate the grade of physical deterioration (from 'mild or no disability', 'severe disability' to 'absolute disability'), the grade of pain (from 'no pain', 'mild pain', 'moderate pain' to 'severe pain') and the grade of emotional trauma (from 'absent', 'minimum', 'moderate', 'acute' to 'severe'). If it was not possible to assess the disability caused by AE, reviewers were instructed to assign 'unknown'.

## 2.3 | Statistical analysis

Proportions were estimated for qualitative variables; and for quantitative variables, central and dispersion measures were estimated. A descriptive analysis of the patients included and the records with AE was performed, inspired by previous works.<sup>18,25</sup>

The prevalence of the main events related to patient safety was estimated by patient (patients with an event, with respect to the total number of patients studied). Periodic control of the database was performed, and coordinators were contacted to reduce the number of missing data to guarantee the quality of the data collected.

Bivariate analysis was performed using Chi<sup>2</sup> tests (if parametric test conditions were met) and Fisher's exact test (non-parametric, if otherwise). The association of quantitative variables was estimated with the Student's *t*-test or Mann-Whitney U test, depending on whether or not the normality criteria were met.

A multivariate logistic regression model was carried out to study the association of the variables with the presence of AE, calibrated and adjusted by patient. The model was started with all significant variables in the univariate analysis and followed a backward modelling strategy (output value  $p < .100$ ). Length of stay was not considered in the multivariate model as it was considered an intermediate variable. To assess the goodness-of-fit and calibration of the model, the Hosmer–Lemeshow (H-L) test was performed.<sup>32,33</sup>

$p$ -values of less than .050 were considered significant.

IBM SPSS Statistics software was used.<sup>34</sup>

## 2.4 | Ethics committee

The study was approved on 19 March 2019 by the Ethics Committee of the Hospital Universitario Ramón y Cajal (reference 057/19), guaranteeing the anonymity and custody of the data gathered, which were transcribed to an anonymised online database, with security mechanisms and safeguarding of personal data.

The study was commissioned by the Ministry of Health of the Community of Madrid. All centres accepted their enrolment in the study.

After the approval of the Ethics Committee, informed consent was not necessary because no intervention was assessed on the participants.

## 3 | RESULTS

### 3.1 | Sample characteristics

A total of 9975 patients met the inclusion criteria, accounting for 81.4% of the 12,247 beds potentially available in the region's public hospitals. The mean and median ages were 63.5 (standard deviation [SD]: 25.5) and 68 (Interquartile range [IR]: 50 to 81), respectively. No relevant differences were found in relation to sex. The most frequent characteristics of the hospitalisation of the patients included were urgent admission (70%), a high complexity hospital (49.8%), or care in a Medical Care Unit (52%). At the time of screening, the median hospital stay was 6 days (IR: 2 to 15). A 82.3% of patients had  $\geq 1$  IRF and 47.6% had  $\geq 3$ . A 74.1% of patients had  $\geq 1$  ERF, a figure that decreased to 25.1% if the peripheral venous catheter was excluded (Table 1).

### 3.2 | Results by phase of the study

Of the initial 9975 patients, 36.6% (3649) had at least one positive screening criterion, comprising a total of 4660

records of possible AE. At the end of this first phase, 55 records were lost.

In the second phase, of the 4,660 records reviewed, 1967 had an AE where their relationship with healthcare was unknown (42.2%). A total of 2378 records were false positives (51%), 311 were non-harm incidents (6.7%), and 4 records could not be classified. Of the 1967 AE, it was determined that 74% (1455) were really healthcare related. From the initial sample, this gave a prevalence of patients with AE of 11.9% (1187 patients with AE; 95%CI: 11.3 to 12.5). Of all the patients with AE, 34.9% (414) had more than one concurrent AE (Figure 1).

### 3.3 | Prevalence of AE and associated factors

Medium complexity hospitals had a higher prevalence of patients with AE (14.8%), followed by high complexity (11.6%), low complexity (11.2%), support (8.5%), long-term care (6.7%) and psychiatric hospitals (2.4%). There was a higher prevalence of patients with AE in males (12.9% vs. 10.9% in females;  $p = .002$ ), in patients aged  $\geq 65$  years (13.4% vs. 10% in patients aged  $< 65$  years;  $p < .001$ ) and as the number of IRF (4.9% for patients without IRF; 15.6% for  $\geq 3$  IRF;  $p < .001$ ) and ERF increased (5.3% for patients without ERF; 28.8% for  $\geq 3$  ERF;  $p < .001$ ). Similarly, a higher prevalence of patients with AE was detected in Intensive Care Units (ICU) (29.7% vs. 13.3% in surgical and 11.4% in medical specialities;  $p < .001$ ), in emergency admissions (12.6% vs. 10.3% in scheduled;  $p = .002$ ) and with the increase in length of hospital stay, being 22.4% in  $\geq 30$  days (compared to 20.4% in 15–30 days, or 4.1% in 0–2 days;  $p < .001$ ) (Table 1).

The gradual increase in ERF and IRF increased the risk of AE, being more than three times higher in patients  $\geq 3$  IRF (OR: 3.24;  $p < .001$ ) and more than twice as high in patients  $\geq 3$  ERF (2.54;  $p < .001$ ), compared to those without these characteristics. Urgent admission (1.43;  $p < .001$ ), surgical interventions (2.15;  $p < .001$ ) and ICU stay (1.60;  $p = .001$ ) also increased the risk of AE. The prevalence of AE was lower in other services (0.15;  $p = .002$ ) and in psychiatric services compared to medical specialities (0.47;  $p = .029$ ) (Table 2).


Adjusted for surgical intervention, no differences were found in the association between being hospitalised in a surgical and a medical service. No significant differences were detected by sex and age when adjusting for the other main variables.

The Hosmer–Lemeshow test was performed to assess the goodness of fit of the model, obtaining a  $p = .389$ ; there were no differences between the observed and expected prevalence.

TABLE 1 Prevalence of adverse events according to patient and hospital admission characteristics

Patient or hospital stay characteristics	Total n (%)	Prevalence of patients with AE	
		n (%)	p
<b>Age</b>			
< 65 years	4559 (46%)	456 (10.0%)	<i>p</i> < .001**
≥ 65 years	5344 (54%)	717 (13.4%)	
<b>Sex</b>			
Woman	4986 (50%)	544 (10.9%)	<i>p</i> = .002*
Man	4.989 (50%)	643 (12.9%)	
<b>Type of hospital</b>			
Low complexity	785 (7.9%)	88 (11.2%)	<i>p</i> < .001**
Medium complexity	3165 (31.7%)	467 (14.8%)	
High complexity	4972 (49.8%)	578 (11.6%)	
Psychiatric	461 (4.6%)	11 (2.4%)	
Long-term care hospital	404 (4.1%)	27 (6.7%)	
Support	188 (1.9%)	16 (8.5%)	
<b>Type of Admitting Service</b>			
Medical specialties	5184 (52%)	591 (11.4%)	<i>p</i> < .001**
Surgical specialties	3123 (31.3%)	414 (13.3%)	
Psychiatric	864 (8.7%)	22 (2.6%)	
Other services	424 (4.2%)	47 (11.1%)	
Intensive medicine	380 (3.8%)	113 (29.7%)	
<b>Hospital stay before screening</b>			
0–2 days	2615 (26.2%)	106 (4.1%)	<i>p</i> < .001**
2–6 days	2552 (25.6%)	213 (8.4%)	
6–15 days	2266 (22.7%)	324 (14.3%)	
15–30 days	1060 (10.6%)	216 (20.4%)	
≥ 30 days	1439 (14.4%)	322 (22.4%)	
Unknown	43 (0.4%)	6 (14%)	
<b>Type of admission</b>			
Scheduled	2939 (29.5%)	303 (10.3%)	<i>p</i> = .002*
Urgent	6993 (70.1%)	878 (12.6%)	
Unknown	43 (0.4%)	6 (14%)	
<b>Surgical intervention</b>			
No intervention	7309 (73.7%)	703 (9.6%)	<i>p</i> < .001**
Intervention	2666 (26.7%)	484 (18.2%)	
<b>Number Intrinsic Risk Factors</b>			
Absence	1761 (17.6%)	87 (4.9%)	<i>p</i> < .001**
1	1729 (17.3%)	169 (9.8%)	
2	1743 (17.5%)	203 (11.7%)	
≥ 3	4742 (47.6%)	728 (15.4%)	
<b>Number Extrinsic Risk Factors</b>			
Absence	2579 (25.7%)	136 (5.3%)	<i>p</i> < .001**
1	5408 (54.2%)	613 (11.4%)	
2	1505 (15.1%)	299 (19.9%)	
≥ 3	483 (4.8%)	139 (28.8%)	
<b>Total</b>	<b>9975</b>	<b>1187 (11.9%)</b>	

Abbreviations: AE, Adverse events. *p*: Ratio comparison (Chi<sup>2</sup> or Fisher's exact test).\**p* < .050; \*\**p* < .001.



**FIGURE 1** Study results tree. AE, Adverse Events; FP, False Positives; NHI, no-harm incidents; PSI, Patient Safety Incidents.

### 3.4 | Characteristics and consequences of the AE

The most frequent type of AE was hospital-acquired infection (HAI) (553; 38%), followed by complications of care (336; 23.1%), complications of a procedure (309; 21.2%) and related to medication (199; 13.7%).

The most common HAI were surgical site infection (196, 13.5%), followed by device-associated bacteraemia (80, 5.5%), urinary tract infection (78, 5.4%) and pneumonias (73, 5%). The most frequent healthcare complications were pressure ulcers (132; 9.1%) and phlebitis (127; 8.7%). The care process during which AE appeared was mainly in the hospitalisation ward (722; 49.8%), during the administration of medical treatment (190; 13.1%).

Of all 1455 AE, 55.2% required medical treatment and 18% required additional surgery to the patients affected by them. A 44.2% of AE increased part of the hospital stay and in 18.4% the AE itself was the cause of readmission (Table 3). Overall, they added a total of 16,227 days of hospitalisation (mean: 9 days/AE; median: 1 day) and 2666 days ICU stay (20 days/AE; 0 days). Patients with severe AE were in hospital for mean of 23 additional days.

A 62.8% of AE had a moderate or severe impact, while 35.5% were mild (for 1.4% of unknown records). On the Rosser scale, 33.3% of the AE identified resulted in severe or absolute physical disability, 25% of AE caused moderate or severe pain and 10% led to emotional trauma of more than a month.

In 11.5% (136) of patients with AE, it had contributed to their death, but no direct causation could be established. Of the 1455 AE related to healthcare, 46.9% (678) were avoidable (Table 4).

## 4 | DISCUSSION

A total of 9975 patients were studied in 34 public hospitals in the Community of Madrid, estimating a prevalence of AE of 11.9%. A higher risk of AE was observed in patients with surgical procedures, an Intensive Care Unit stay and in hospitals of medium complexity. A profile of a patient who suffers AE is an older adult, male, with urgent nature of admission, ICU or surgical stay, with prolonged hospital days, with a previous surgical intervention and with the presence of IRF and ERF. More than 9 out of 10 AE required additional assistance, and more than a half had a moderate or severe impact and increased the length of the stay or was the cause of admission.

The Harvard Medical Practice School methodology has been replicated on multiple occasions, although with significant differences, depending on the type of retrospective review carried out. Initially, this technique was used in the form of longitudinal reviews that estimated the incidence, providing an adequate approximation to the epidemiological variables related to AE and enabling the study of causality relations.<sup>35</sup> Using this methodology, in the United States, Brennan et al., in 1991, obtained an incidence of AE resulting from medical negligence of 3.7%<sup>8</sup> (sample [ $n$ ] = 31,429); and later, in 1992, it was obtained similar results of 2.9% in Utah and Colorado ( $n$  = 14,732).<sup>10</sup> Later, other longitudinal studies wanted to identify all kind of AE and obtained higher incidence values: in Australia, a study in 1995 detected an incidence of 16.6% AE ( $n$  = 14,179)<sup>9</sup>; and, in Spain, the ENEAS (hospital-specific) in 2005, detected incidence of AE of 9.3% ( $n$  = 5624).<sup>13</sup>

However, these longitudinal studies are often long and costly, requiring a detailed analysis of the entire

TABLE 2 Risk of developing an adverse event by hospitalised patients, according to the characteristics of the patient or the hospital stay

Characteristics of the patient or the hospital stay	Total, n (%)	Prevalence AE, n (%)	Odds Ratio	CI 95%	p
<b>Age</b>					
<65 years	4559 (46%)	456 (10%)	1.00	-	-
≥65 years	5344 (54%)	717 (13.4%)	0.92	0.80 to 1.06	.289
<b>Sex</b>					
Woman	4986 (50%)	544 (10.9%)	1.00	-	-
Male	4989 (50%)	643 (12.9%)	1.10	0.97 to 1.25	.178
<b>Type of hospital</b>					
Low complexity	785 (7.9%)	88 (11.2%)	1.00	-	-
Medium complexity	3165 (31.7%)	467 (14.8%)	1.45	1.12 to 1.87	<.001**
High complexity	4972 (49.8%)	578 (11.6%)	1.00	0.78 to 1.28	.965
Psychiatric	461 (4.6%)	11 (2.4%)	0.62	0.38 to 1.03	.070
Long-term care hospital	404 (4.1%)	27 (6.7%)	1.01	0.42 to 2.46	.963
Support	188 (1.9%)	16 (8.5%)	0.89	0.50 to 1.58	.691
<b>Type of admission</b>					
Scheduled	2939 (29.5%)	303 (10.3%)	1.00	-	-
Urgent	6993 (70.1%)	878 (12.6%)	1.43	1.20 to 1.70	<.001**
<b>Surgical intervention</b>					
No intervention	7309 (73.7%)	703 (9.6%)	1.00	-	-
Intervention	2666 (26.7%)	484 (18.2%)	2.15	1.79 to 2.57	<.001**
<b>Type of service</b>					
Medical speciality	5184 (52%)	591 (11.4%)	1.00	-	-
Surgical speciality	3123 (31.3%)	414 (13.3%)	1.01	0.84 to 1.21	.991
Psychiatric	864 (8.7%)	22 (2.6%)	0.47	0.25 to 0.89	.029*
Other services	424 (4.2%)	47 (11.1%)	0.16	1.12 to 2.29	.002*
Intensive medicine	380 (3.8%)	113 (29.7%)	1.60	1.17 to 2.17	.001*
<b>Number of Intrinsic Risk Factors</b>					
Absence	1761 (17.6%)	87 (4.9%)	1.00	-	-
1	1729 (17.3%)	169 (9.8%)	1.99	1.50 to 2.64	<.001**
2	1743 (17.5%)	203 (11.7%)	2.38	1.80 to 3.14	<.001**
≥3	4742 (47.6%)	728 (15.4%)	3.24	2.50 to 4.19	<.001**
<b>Number of Extrinsic Risk Factors</b>					
Absence	2579 (25.7%)	136 (5.3%)	1.00	-	-
1	5408 (54.2%)	613 (11.4%)	1.37	1.10 to 1.70	.020*
2	1505 (15.1%)	299 (19.9%)	2.32	1.82 to 2.96	<.001**
≥3	483 (4.8%)	139 (28.8%)	2.54	1.82 to 3.54	<.001**
Constant	-	-	0.02	0.01 to 0.03	<.001**

Notes: AE: Adverse event; CI 95%: 95% confidence interval; p: estimated p-value in logistic regression.

Multivariate logistic regression analysis, adjusted for: sex, age, type of hospital, type of admission, type of surgery, type of service and number of intrinsic and extrinsic risk factors.

\* $p < .050$ ; \*\* $p < .001$ .

patient episode.<sup>36</sup> ESHMAD therefore opted for a cross-sectional design, previously validated and considered appropriate for the estimation and characterisation of AE.<sup>28,37,38</sup> Thus, compared with other cross-sectional

studies, the prevalence of ESHMAD AE (11.9%) is similar to that of IBEAS (10.5%; conducted in 2009 in hospitals in Colombia, Argentina, Costa Rica, Mexico and Peru)<sup>25</sup>; but higher than the one found in two studies

TABLE 3 Types and consequences of AE

Characteristics of the AE	Total AE	
	n	%
Type of AE		
Hospital acquired infections	553	38%
Complications in care	336	23.1%
Complications of a procedure	309	21.2%
Adverse effects of medication	199	13.7%
Other consequences	58	4%
Additional assistance as a result of the AE		
Medical treatment or rehabilitation (antibiotics, dressings, etc.)	797	55.2%
Additional surgical intervention	260	18%
No additional treatment or measures were required	109	7.5%
Life support intervention or treatment (orotracheal intubation, etc.)	106	7.3%
An additional test was required (x-ray, culture, etc.) or other procedure	104	7.2%
It required a higher level of observation and monitoring	69	4.8%
Modification of hospitalisation by the AE		
Unknown	20	1.4%
It did not lengthen the stay	507	35.1%
Extended part of the stay	638	44.2%
Cause of readmission	280	19.4%
<b>Total</b>	<b>1445</b>	<b>100%</b>

Abbreviation: AE, Adverse event.

that analysed the period between 2005 and 2008 on hospitals in the Valencian Community, Spain (6% and 5.8%, respectively).<sup>12,39</sup>

These and other results from the Harvard Medical Practice School methodology have been compiled in systematic reviews such as those carried out by De Vries et al. in 2008,<sup>40</sup> by Schwendimann et al. in 2018<sup>41</sup> and by Panagioti et al. in 2019.<sup>42</sup> The latter includes a meta-analysis that determined a prevalence of patients with AE of 12%, this being a result entirely consistent with that obtained by ESHMAD.

The prevalence of patients with AE was higher in middle-complexity hospitals (14.8%) than in high- and low-complexity hospitals (11.6% and 11.2%). This differs from the results obtained by some studies, in which the increase in hospital complexity was associated with a higher frequency of AE, especially from certain interventions performed on patients with numerous comorbidities.<sup>13,14,25</sup>

TABLE 4 Patient impact and avoidability of AE

Impact and avoidability of the AE	Total AE	
	n	%
Severity <sup>a</sup>		
Unknown	28	1.9%
Mild	514	35.3%
Moderate	612	42.1%
Severe	301	20.7%
Physical deterioration		
Unknown	247	17%
Mild or no disability	738	50.7%
Severe disability	254	17.5%
Absolute disability	216	14.8%
Pain		
Unknown	571	39.5%
No pain	216	14.9%
Mild pain	302	20.9%
Moderate pain	273	18.9%
Severe pain	83	5.7%
Emotional trauma <sup>b</sup>		
Unknown	985	68.2%
Absent	206	14.3%
Minimum	102	7.1%
Moderate	95	6.6%
Acute	30	2.1%
Severe	27	1.9%
Death		
No	1278	87.8%
Yes	177	12.2%
Avoidability		
Unknown	361	24.9%
No	406	28.2%
Yes	678	46.9%
<b>Total</b>	<b>1455</b>	<b>100%</b>

Abbreviation: AE, Adverse event.

<sup>a</sup>Severity: Mild: it did not modify hospital stay; Moderate: it resulted in readmission or lengthened the hospital stay; Severe: if it led to a surgical intervention or contributed to the patient's death.

<sup>b</sup>Minimal emotional trauma: with recovery in less than 1 month; Moderate: with recovery between 1 and 6 months; Acute: with recovery between 6 and 12 months; Severe: longer than 12 months.

However, in other studies, no differences in complexity were detected, therefore, this would be an aspect that could benefit from complementary studies.<sup>5,17</sup>

The prevalence of AE was higher in ICU (29.7%) and surgical services (15.2%), although these are lower than the figures obtained in the Panagioti et al.'s review (34%



and 20%, respectively).<sup>42</sup> However, this is a common finding for most studies that use the Harvard Medical Practice School methodology, regardless of their cross-sectional or longitudinal design.<sup>11–14,16,19,25</sup>

In psychiatric services, in both specialised and acute hospitals, a prevalence of 2.6% has been found. This datum is slightly lower than studies carried out specifically in psychiatric hospitals, which put it between 5.4%<sup>43</sup> and 13.4%.<sup>44</sup> Our lower prevalence may be due to two reasons. First, most of the AEs identified in these studies are adverse drug effects, which are underestimated in a cross-sectional design. The second one is that those studies used specific screening tools for AE in psychiatry and used more recent definitions of AE adapted to the particularities of the psychiatric patient.<sup>45</sup> In this study, we have attempted to use the same tool regardless of the service to be able to compare the type of hospital and service with the same measurement instrument. Future articles should adapt the approach to the psychiatric reality to give a more accurate measure of the problems in this area.

The avoidability of AE was 47%, although 25% of the sample did not record this data, so it may be slightly underestimated. However, this is consistent with the results of the meta-analysis of Panagioti et al., which estimates it at 50%.<sup>42</sup>

The main type of AE identified was HAI (38%), followed by complications in care (23%) and problems related to a procedure (21%). In the meta-analysis by Schwendimann *et al.*<sup>41</sup>, the most frequent AE were those related to a procedure (40%), followed by those related to medication (19.3%) and HAI (17.7%). This discrepancy may be due to the fact that the same criteria were not used to define HAI (although ESHMAD adopted the valid and specific EPINE criteria for this objective<sup>26</sup>); In the IBEAS, the most frequent were HAI and procedure-related problems.<sup>25</sup>

In the ESHMAD, only 13% of AE were related to medication. In this respect, another study, carried out in Spain between 2005 and 2013, estimated a frequency of 16.3% of this type of EA on a sample of 35,103 patients, noting a direct relationship between avoidability and severity.<sup>46</sup>

Moderate severity AE were the most frequent (42%), followed by mild and severe AE. This is consistent with that obtained in other cross-sectional studies,<sup>25,35</sup> but differs from that found in longitudinal studies, in which mild AE are usually more frequent (50%).<sup>40,42</sup>

Cross-sectional and longitudinal studies have their own particularities, which could explain some of the differences between the results derived from both types of studies: the longitudinal ones make it possible to estimate the incidence of AE and establish hypothesis of causality,<sup>35</sup> but they are also usually less operational because they present a greater duration and need of resources.<sup>36</sup>

A common limitation of cross-sectional studies, such as ESHMAD, is that long-term findings (such as prolonged hospital stay, moderate–severe HAI or consequences) may be overrepresented, to the detriment of those that prolong it to a lesser extent or even reduce it (such as mild AE or premature discharge).<sup>35,36</sup> However, this should not affect the main objective of the study, which was to evaluate the condition of hospitals in the region, prioritising the AE that have the greatest impact on health management in the hospital setting. In addition, cross-sectional studies, by making a more specific selection of the sample, allow to study the prevalence of AE efficiently and with a high ability to identify them.<sup>28,37,38</sup>

Another limitation of ESHMAD, derived from the Harvard Medical Practice School methodology, is the reviewer subjectivity when establishing the possible relationship of AE with health care and its avoidability. However, this design was previously validated for the identification of AE and has optimal levels of consistency between evaluators. However, it would be interesting to develop more objective analysis tools to improve the validity of results.<sup>28,37,38</sup>

That said, ESHMAD is a pioneer, being carried out simultaneously in all the hospitals of the Community of Madrid to ascertain the current situation regarding patients safety in the region. Its results identify areas for improvement, enabling the development of policies and strategies to mitigate the impact of the AE. The conducting of the study required the recruitment of a large number of health professionals from different fields and competencies, training them in aspects essential to the identification and systematic analysis of AE by means of cascade training. In addition to the positive impact on the institutional culture itself, an efficient methodology has been used, creating synergies between surveillance systems and making use of complementary approaches from different professional areas. All this has been done by applying a validated methodology, such as the screening questionnaires and MRF2,<sup>28</sup> but which has also been widely used in different regions and health systems before.<sup>5,8–12,14–19</sup> Therefore, in addition to studying the epidemiology of AE, ESHMAD is also designed to be a reproducible, practical and reliable AE surveillance and monitoring system.<sup>35</sup>

## 5 | CONCLUSIONS

Hospitals in the Community of Madrid have a prevalence of AE consistent with that obtained in other epidemiological studies conducted with a similar methodology. These AE produce avoidable and potentially improvable harm. In addition, prolonged hospital stay and resource

consumption – derived from additional medical and surgical treatment – are clear examples of lost opportunities.

Patients with several comorbidities, who are often in a worse clinical condition and require more invasive procedures, develop AE more often. Likewise, HAI is the most common type of AE, so the development of specific measures to prevent nosocomial infections would be a beneficial strategy for all hospitals in the region.

ESHMAD has made it possible to estimate the frequency and characteristics of AE in all public hospitals in the Community of Madrid. This will identify areas for improvement and promote patient safety strategies that will improve the quality of care provided by healthcare providers.

The lack of changes in the patient safety results compared with that obtained globally in the last 20 years allows us to conclude that it is necessary to put the focus again on AE.

## CONTRIBUTORS

ESHMAD Director Group and external advisers: Asunción Colomer Rosas, Inmaculada Mediavilla Herrera, M<sup>a</sup> José Esteban Niveiro, Nieves López Fresneña, Cristina Díaz-Agero Pérez, Pedro Ruiz Lopez, Isabel Carrasco Gonzalez, Cristina Navarro Royo, Carmen Albéniz Lizarraga, Yuri Fabiola Villan Villan, Ana Isabel Alguacil Pau, Alicia Díaz Redondo, Rosa Plá Mestre, Dolores Martín Ríos, Angels Figuerola Tejerina, Carlos Aibar Remón, José Joaquín Mira Soves, Juana Requena Puche, Idelfonso González Solana, Montserrat Salcero Guijarro, Delia Fernández Redondo, Esteban del Pozo García, Cornelia Bischofberger Valdés, Libertad Martín Prieto, Marta Grande Arnesto, Beatriz Nieto Pereda, Ana Herranz Alonso, Alicia Díaz Redondo, Laura Rubio Cirilo, Rafael Martos Martínez, María Teresa Ledo Varela, María Vicenta García Rosado, Jesús Minaya Saíz, María Jesús Labrador Domínguez, María José Pita López, Elia Mayoral Peccis, Marco Antonio Espinel Ruíz, Ana Polo Parada, Emely García Carrasco, Carlos Aranda Cosgaya, Carmen Gutiérrez Bezón, María de Sebastián Rueda, Miguel Ruíz Álvarez, Mercedes Vinuesa Sebastián, María Dolores Montserrat Capella, Carolina Ruíz Entrecanales, Sonia de Miguel Fernández, María Pilar González Sánchez, Felisa Jaén Herreros, María José Durá Jiménez, Carmen de Burgos Lunar, Anabel Alguacil Pau, María Ángel Valcárcel de la Iglesia, Laura Moratilla Monzó, Mercedes Ortiz Otero, Margarita Mosquera González, Susana Lorenzo Martínez, María Dolores Martín Ríos, Carolina Lucas Molina, María Teresa Sayalero Martín, María Dolores Calles Gato, Juan José Granizo Martínez, Juan Vega Barea, Eva Jiménez González de Buitrago, Inés Fernández Jiménez,

Cristina García Fernández, Inmaculada López Carrillo, Ana Robustillo Rodela, Elena Ramírez García, Romina Sánchez Gómez, Nieves Franco Garrobo, Nieves Plana Farrá, Marta Macías Maroto, Marta Soler Vigil, Gonzalo de las Casas Cámara, Nuria Gálvez Carranza, Ana Belén Jiménez Muñoz, Belén Martínez Mondéjar, Beatriz Isidoro Fernández, Lourdes Sainz de los Terreros Soler, Carolina del Valle Giráldez García, Ruth González Ferrer, Guillermo Ordóñez León, Miguel Miró Murillo, Rosalía Hernández Holgado, Pilar Paloma Blanco Hernández, José Manuel Carrascosa Bernaldez, Sonia Fraile Gil, Beatriz Fidalgo Hermida, Francisco López Rodríguez Arias, Verónica Aranaz Ostáriz, María Pardo Ortiz.

## AUTHOR CONTRIBUTIONS


Conception and design: Jesús María Aranaz-Andrés, José L. Valencia-Martín, Alberto Pardo-Hernández. Acquisition of data: Diego San José-Saras, Paloma Moreno-Nunez, Jorge de Vicente-Guijarro, ESHMAD Director Group and external advisers. Analysis and interpretation of data: Jose L. Valencia-Martín, Jorge de Vicente-Guijarro, Diego San José-Saras. Drafting the manuscript: Jorge de Vicente-Guijarro, Diego San José-Saras. Critical revision of the manuscript for important intellectual content: José L. Valencia-Martín, Jesús María Aranaz-Andrés, Paloma Moreno-Nunez, Alberto Pardo-Hernandez. Supervision: Jesús María Aranaz-Andrés, José L. Valencia-Martín, Alberto Pardo-Hernández.

## CONFLICT OF INTERESTS

None.


## ORCID

José L. Valencia-Martín  <https://orcid.org/0000-0003-0841-9992>

Jorge Vicente-Guijarro  <https://orcid.org/0000-0001-7447-9390>

Diego San Jose-Saras  <https://orcid.org/0000-0002-7063-5912>

Paloma Moreno-Nunez  <https://orcid.org/0000-0002-8873-8688>

Jesús María Aranaz-Andrés  <https://orcid.org/0000-0002-3658-0321>

## REFERENCES

- Mitchell PH. Defining patient safety and quality care. In: Hughes RG, ed. *Patient Safety and Quality: An Evidence-Based Handbook for Nurses*. Advances in Patient Safety. Agency for Healthcare Research and Quality (US); 2008. Accessed April 1, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK2681/>
- Patient safety assessment manual 2nd edition [Internet]*. : World Health Organization; 2016. [cited 2022 Jan 11]. Available from: <https://www.who.int/publications-detail-redirect/9789290221203>

3. Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. *Lancet*. 2018;392(10160):2203-2212. doi:10.1016/S0140-6736(18)31668-4
4. Makary MA, Daniel M. Medical error—the third leading cause of death in the US. *BMJ*. 2016;353:i2139. doi:10.1136/bmj.i2139
5. Rafter N, Hickey A, Conroy RM, et al. The Irish National Adverse Events Study (INAES): the frequency and nature of adverse events in Irish hospitals—a retrospective record review study. *BMJ Qual Saf*. 2017;26(2):111-119. doi:10.1136/bmjqs-2015-004828
6. Institute of Medicine (US) Committee on Quality of Health Care in America. In: Kohn LT, Corrigan JM, Donaldson MS, eds. *To Err Is Human: Building a Safer Health System*. National Academies Press (US); 2000. Accessed March 27, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK225182/>
7. Institute for Healthcare Improvement. IHI Global Trigger Tool Guide. 2006 [Internet]. [cited 2021 Sep 30]. Available from: <https://somuca.es/wp-content/uploads/2011/11/GlobalTriggerToolGuide.pdf>
8. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. *N Engl J Med*. 1991;324(6):370-376. doi:10.1056/NEJM199102073240604
9. Wilson RM, Runciman WB, Gibberd RW, Harrison BT, Newby L, Hamilton JD. The Quality in Australian Health Care Study. *Medical Journal of Australia*. 1995;163(9):458-471. doi:10.5694/j.1326-5377.1995.tb124691.x
10. Thomas EJ, Studdert DM, Burstin HR, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. *Med Care*. 2000;38(3):261-271. doi:10.1097/00005650-200003000-00003
11. Vincent C, Neale G, Woloshynowych M. Adverse events in British hospitals: preliminary retrospective record review. *BMJ*. 2001;322(7285):517-519. doi:10.1136/bmj.322.7285.517
12. Requena J, Aranaz JM, Gea MT, et al. Evolution of the adverse effects prevalence related to healthcare in hospitals of the Valencia community. *Rev Calid Asist*. 2010;25(5):244-249. doi:10.1016/j.cali.2010.03.007
13. Aranaz-Andrés JM, Aibar-Remón C, Vitaller-Murillo J, Ruiz P. *Estudio nacional sobre los efectos adversos ligados a la hospitalización: ENEAS 2005*. Ministerio de Sanidad y Consumo; 2006.
14. Sousa P, Uva AS, Serranheira F, Uva MS, Nunes C. Patient and hospital characteristics that influence incidence of adverse events in acute public hospitals in Portugal: a retrospective cohort study. *International J Qual Health Care*. 2018;30(2):132-137. doi:10.1093/intqhc/mzx190
15. Mostaza JL, Muínelo I, Teijo C, Pérez S. Prevalence and severity of adverse effects in hospitalized patients. *Med Clin (Barc)*. 2005;124(2):77-78. doi:10.1157/13070462
16. Mendes W, Pavão ALB, Martins M, Travassos C. The application of Iberoamerican study of adverse events (IBEAS) methodology in Brazilian hospitals. *International J Qual Health Care*. 2018;30(6):480-485. doi:10.1093/intqhc/mzy055
17. Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. *CMAJ*. 2004;170(11):1678-1686. doi:10.1503/cmaj.1040498
18. Sommella L, de Waure C, Ferriero AM, et al. The incidence of adverse events in an Italian acute care hospital: findings of a two-stage method in a retrospective cohort study. *BMC Health Serv Res*. 2014;14:358. doi:10.1186/1472-6963-14-358
19. Davis P, Lay-Yee R, Briant R, Ali W, Scott A, Schug S. Adverse events in New Zealand public hospitals I: occurrence and impact. *N Z Med J*. 2002;115(1167):U271.
20. Aranaz-Andrés JM, Aibar C, Limón R, et al. A study of the prevalence of adverse events in primary healthcare in Spain. *Eur J Public Health*. 2012;22(6):921-925. doi:10.1093/eurpub/ckr168
21. Estudio EARCAS. *Eventos adversos en residencias y centros asistenciales sociosanitarios*. Ministerio de Sanidad, Política Social e Igualdad; 2011.
22. Estrategia Seguridad del Paciente del Sistema Nacional de Salud 2015–2020. Ministerio de Sanidad, Política Social e Igualdad. 2016 [Internet]. [cited 2022 Jul 9]. Available from: <https://seguridaddelpaciente.es/recursos/documentos/2015/Estrategia%20Seguridad%20del%20Paciente%202015-2020.pdf>
23. Estrategia de Seguridad del Paciente 2015-2020. Consejería de Sanidad de la Comunidad de Madrid. 2015; [Internet]. [cited 2022 Jul 9]. Available from: [https://www.comunidad.madrid/sites/default/files/estrategia\\_de\\_seguridad\\_del\\_paciente\\_2015-2020\\_sermas\\_rev.pdf](https://www.comunidad.madrid/sites/default/files/estrategia_de_seguridad_del_paciente_2015-2020_sermas_rev.pdf)
24. Valencia-Martín JL, Martín-Delgado J, Pardo-Hernández A, et al. The Study on Safety in Hospitals in the Region of Madrid (ESHMAD) design: Screening and analysis of incidents and adverse events. *J Healthc Qual Res*. Published online May 6, 2021:S2603-6479(21)00035-X. doi:10.1016/j.jhqr.2021.03.007
25. Aranaz-Andrés JM, Aibar-Remón C, Limón-Ramírez R, et al. Prevalence of adverse events in the hospitals of five Latin American countries: results of the “Iberoamerican Study of Adverse Events” (IBEAS). *BMJ Qual Saf*. 2011;20(12):1043-1051. doi:10.1136/bmjqs.2011.051284
26. Estudio de Prevalencia de Infecciones Nosocomiales. Informe España. 2019. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. [cited 2022 Mar 27]. Available from: <https://epine.es/api/documento-publico/2019%20EPINE%20Informe%20Espa%C3%B1a%2027112019.pdf/reports-esp>
27. Protocolo Estudio EPINE-EPPS. 2019. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. [cited 2022 Jul 22]. Available from: <https://sagunto.san.gva.es/documentos/7967159/8195564/Protocolo+Epine+2019.pdf>
28. Woloshynowych M, Neale G, Vincent C. Case record review of adverse events: a new approach. *Qual Saf Health Care*. 2003;12(6):411-415. doi:10.1136/qhc.12.6.411
29. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. *Eur J Clin Invest*. 2010;40(1):35-53. doi:10.1111/j.1365-2362.2009.02234.x
30. *Conceptual framework for the International Classification for Patient Safety*. World Health Organization. 2009. Available from: [http://www.who.int/patientsafety/taxonomy/icps\\_full\\_report.pdf](http://www.who.int/patientsafety/taxonomy/icps_full_report.pdf)
31. Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? *Int J Epidemiol*. 1978;7(4):347-358. doi:10.1093/ije/7.4.347
32. Nick TG, Campbell KM. Logistic regression. *Methods Mol Biol*. 2007;404:273-301. doi:10.1007/978-1-59745-530-5\_14
33. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for

- validation. *Eur Heart J*. 2014;35(29):1925-1931. doi:10.1093/eurheartj/ehu207
34. Corp IBM. *IBM SPSS Statistics for Windows, Version 22.0*. IBM Corp; 2013.
35. Aranaz Andrés JM, Limón Ramírez R, Aibar Remón C, et al. Comparison of two methods to estimate adverse events in the IBEAS Study (Ibero-American study of adverse events): cross-sectional versus retrospective cohort design. *BMJ Open*. 2017;7(10):e016546. doi:10.1136/bmjopen-2017-016546
36. Michel P, Quenon JL, de Sarasqueta AM, Scemama O. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. *BMJ*. 2004;328(7433):199-190. doi:10.1136/bmj.328.7433.199
37. Walshe K. The reliability and validity of adverse-event measures of the quality of health care:417.
38. Neale G, Woloshynowych M. Retrospective case record review: a blunt instrument that needs sharpening. *Qual Saf Health Care*. 2003;12(1):2-3. doi:10.1136/qhc.12.1.2
39. Aranaz-Andres JM, Agra Y. *Medicina Clinica*. Vol 135. Elsevier; 2010.
40. de Vries EN, Ramrattan MA, Smorenburg SM, Gouma DJ, Boermeester MA. The incidence and nature of in-hospital adverse events: a systematic review. *Qual Saf Health Care*. 2008;17(3):216-223. doi:10.1136/qshc.2007.023622
41. Schwendimann R, Blatter C, Dhaini S, Simon M, Ausserhofer D. The occurrence, types, consequences and preventability of in-hospital adverse events - a scoping review. *BMC Health Serv Res*. 2018;18(1):521. doi:10.1186/s12913-018-3335-z
42. Panagioti M, Khan K, Keers RN, et al. Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis. *BMJ*. Published online July 17. 2019;366:l4185. doi:10.1136/bmj.l4185
43. Marcus SC, Hermann RC, Frankel MR, Cullen SW. Safety of Psychiatric Inpatients at the Veterans Health Administration. *Psychiatr Serv*. 2018;69(2):204-210. doi:10.1176/appi.ps.201700224
44. Cullen SW, Xie M, Vermeulen JM, Marcus SC. Comparing Rates of Adverse Events and Medical Errors on Inpatient Psychiatric Units at Veterans Health Administration and Community-based General Hospitals. *Med Care*. 2019;57(11):913-920. doi:10.1097/MLR.0000000000001215
45. Marcus SC, Hermann RC, Cullen SW. Defining Patient Safety Events in Inpatient Psychiatry. *J Patient Saf*. 2021;17(8):e1452-e1457. doi:10.1097/PTS.0000000000000520
46. Mollar-Maseres JB, Aranaz-Andrés JM, Martin-Moreno JM, et al. Adverse events related to medication in hospitals from the Valencian Community. EPIDEA Study 2005-2013. *Rev Esp Quimioter*. 2017;30(5):319-326.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Valencia-Martín JL, Vicente-Guijarro J, San Jose-Saras D, et al. Prevalence, characteristics, and impact of adverse events in 34 Madrid hospitals. The ESHMAD study. *Eur J Clin Invest*. 2022;52:e13851. doi: [10.1111/eci.13851](https://doi.org/10.1111/eci.13851)